Intravesical Gem/Doce in Patients With NMIBC

Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer (NMIBC) is a well-established treatment for preventing or delaying tumor recurrence after tumor resection. For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) can be effective as first-line; nevertheless, the response rate to BCG is suboptimal with many patients failing treatment. Following BCG-failure, however, very few effective therapeutic options exist besides life-changing cystectomy. Recent shortages of BCG have pushed the use of alterna

Trial Details

NCT ID
NCT05644041
Phase
PHASE2
Sponsor
University of Arizona
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • gemcitabine + docetaxel
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648

Key Eligibility Criteria

  • Patients able to consent in English or Spanish; provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female ages ≥18 years.
  • Patients with intermediate or high-risk non-muscle-invasive UC of the bladder and no previous BCG treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →